𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer

✍ Scribed by Masanori Noguchi; Kyogo Itoh; Shigetaka Suekane; Akihisa Yao; Norie Suetsugu; Kazuko Katagiri; Akira Yamada; Hideaki Yamana; Shinshi Noda

Book ID
108582390
Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
358 KB
Volume
95
Category
Article
ISSN
1347-9032

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Infusion of dendritic cells pulsed with
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
✍ Murphy, G.P.; Tjoa, B.A.; Simmons, S.J.; Jarisch, J.; Bowes, V.A.; Ragde, H.; Ro πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 225 KB πŸ‘ 2 views

## Background: A phase ii trial was conducted to assess the efficacy of infusions of dendritic cells (dc) and two hla-a2-specific psma peptides (psm-p1 and -p2). this report describes thirty three subjects with hormone-refractory metastatic prostate cancer without prior vaccine therapy history who

Allogeneic retrovirally transduced, IL-2
Allogeneic retrovirally transduced, IL-2- and IFN-Ξ³-secreting cancer cell vaccine in patients with hormone refractory prostate cancerβ€”a phase I clinical trial
✍ T. H. Brill; H. R. KΓΌbler; H. v. Randenborgh; F. Fend; H. Pohla; J. Breul; R. Ha πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 856 KB

## Abstract ## Background The purpose of this vaccine study was to determine the safety and feasibility of vaccination with an allogeneic prostate carcinoma cell line, LNCaP, expressing recombinant interleukin‐2 (IL‐2) and interferon‐γ (IFN‐γ) and to evaluate the efficacy of inducing tumor‐specifi